Use of hydroxyurea and recombinant erythropoietin in management of homozygous β0 thalassemia

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 9, 2002, Pages 777-778

  Kohli Kumar, Mudra ^a,c   Marandi, Hossain ^a   Keller, Margaret A ^b   Guertin, Kathy ^a   Hvizdala, Eva ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

Erythropoietin; Hydroxyurea; Thalassemia

Indexed keywords

HEMOGLOBIN; HYDROXYUREA; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BODY GROWTH; CASE REPORT; CHILD; DRUG EFFICACY; FEMALE; HEMOGLOBIN DETERMINATION; HOMOZYGOSITY; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT;

ANTISICKLING AGENTS; BETA-THALASSEMIA; CHILD; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEPATOMEGALY; HUMANS; HYDROXYUREA; SPLENOMEGALY; STEM CELL TRANSPLANTATION;

EID: 0036898542     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200212000-00021     Document Type: Article

References (17)

1. Styles L, Lewis B, Foote D, et al. Preliminary report: Hydroxyurea produces significant clinical response in thalassemia intermedia. Ann N Y Acad Sci 1998; 850:461-462.
2. Arruda VR, Lima CSP, Saad STO, et al. Successful-use of hydroxyurea in beta-thalassemia major. N Engl J Med 1997;336:964.
3. Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet 1997;350:491-2.
4. Breymann C, Fibach E, Visca E. et al. Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. J Matern Fetal Med 1999;8:1-7.
5. Saxon BR, Waye JS, Olivieri NG. Increase in hemoglobin concentration during therapy with hydroxyurea in Cooley's anemia. Ann N Y Acad Sci 1998;850:459-60.
6. Saxon BR, Rees D, Olivieri NF. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in β thalassaemia. Br J Haematol 1998;101:416-19.
7. Hoppe C, Vichinsky E, Lewis B, et al. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol 1999;62:221-7.
8. Gγ-158 C→T mutation on the HbF level. Am J Hematol 2000;64:151-5.
9. Nisli G, Kavakli K, Aydinok Y, et al. Recombinant erythropoietin trial in children with transfusion-dependent homozygous β-thalassemia. Acta Haematol 1997;98:199-203.
10. Loukipoulos D, Voskaridou E, Stamoulakatou A. et al. Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci 1998;850:120-8.
11. Olivieri NF, Weatherall DJ. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet 1998;7:1655-8.
12. Steinberg MH, Rodgers GP. Reviews in molecular medicine. Medicine 2001; 80:328-44.
13. Yavarian M, Harteveld CL, Batelaan D, et al. Molecular spectrum of β-thalassemia in the Iranian province of Hormozgan. Hemoglobin 2001;25:35-43.
14. Vrettou C, Kanavakis E, Traeger-Synodinos J. et al. Hemoglobin 2000;24:203-20.
15. Merat A, Haghshenas M, Mostafavi Pour Z. et al. β-thalassemia in southwestern Iran. Hemoglobin 1993;17:427-37.
16. Dimovski AJ, Adekile AD, Divoky V, et al. Polymorphic pattern of the (AT) X (T) Y motif at 530 5′ to the beta-globin gene in over 40 patients homozygous for various beta-thalassemia mutations. Am J Hematol 1994;45:51-7.
17. de Alarcon PA, Donovan ME, Forbes GB, et al. Iron absorption in the thalassemia syndromes and its inhibiton by tea. N Engl J Med 1979;300:5-8.